PT Wahana Inti Makmur Tbk (NASI) Fair Value & Analysis
Consumer Defensive · ID · Market cap 97.7B IDR
Fair value as of: Jul 16, 2026
From 7 valuation models · updated today
Share price +12.0% over the past month.
Price vs Fair Value (12 months)
12‑month range 83.00 IDR – 188.00 IDR · fair‑value band 37.58 IDR – 81.95 IDR · the 121.00 IDR price screens above the 59.77 IDR fair value. As of Jul 16, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
PT Wahana Inti Makmur Tbk (NASI) currently trades at 121.00 IDR, while our model-based Fair Value estimate is 59.77 IDR, implying the stock looks roughly 50.6% overvalued today. We read business quality at 48/100 (below-average quality), in the Consumer Defensive sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, PT Wahana Inti Makmur Tbk generated revenue of 47.9B IDR at a net margin of -9.2%. Revenue declined 57.5% year over year. It earns a return on equity of -7.6%. Net debt stands at 5.7B IDR. Fundamentals as of Jul 16, 2026
Our scenario range runs from 37.58 IDR (bear case) to 81.95 IDR (bull case); at 121.00 IDR, the current price sits above that range. The share trades about 49% below its 52-week high and 68% above its 52-week low, currently below its 200-day average. For context, the median of 10 Consumer Defensive peers we cover trades at 76% fair-value upside, at -51%, NASI screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 16, 2026. TTM = trailing twelve months.
About the company
PT Wahana Inti Makmur Tbk produces and sells rice in Indonesia. The company offers aromatic, healthy, tarabas, medium grain, premium grade, and basmati rice, as well as private labeled rice. The company was founded in 2015 and is headquartered in Jakarta Barat, Indonesia.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
PT Wahana Inti Makmur Tbk reported revenue of 59.6B IDR in FY2025 versus 45.2B IDR in FY2021, a compound +7.2%/yr. Reported net income was −3.7B IDR in FY2025.
Is NASI fairly valued? → Check now
Similar stocks
10 more Farm Products stocks, each showing price versus our Fair Value estimate (as of Jul 16, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Archer-Daniels-Midland Company ADM | $76.29 | $46.97 | -38% |
| MHP SE MHPC | $0.0854 | $0.0100 | -88% |
| Muyuan Foods Group 002714 | ¥33.95 | ¥119.07 | +251% |
| Wens Foodstuff Group 300498 | ¥12.49 | ¥12.08 | -3% |
| Mowi ASA MOWI | kr 204.00 | kr 112.48 | -45% |
| SalMar ASA SALM | kr 574.50 | kr 57.93 | -90% |
| Fujian Wanchen Food Group 300972 | ¥177.00 | ¥311.94 | +76% |
| PT Charoen Pokphand Indonesia Tbk, CPIN | 3,170 IDR | 7,228 IDR | +128% |
| Charoen Pokphand Foods Public Company CPF | 19.20 THB | 57.92 THB | +202% |
| PT Triputra Agro Persada Tbk TAPG | 1,525 IDR | 4,521 IDR | +196% |
Explore undervalued stocks
More undervalued Consumer Defensive stocks →
Frequently asked questions
Is PT Wahana Inti Makmur Tbk (NASI) undervalued?
What is the fair value of NASI?
What is the quality score of NASI?
What is the revenue of PT Wahana Inti Makmur Tbk (NASI)?
What is the net profit margin of NASI?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Tell me when PT Wahana Inti Makmur Tbk reaches its Fair Value
Just your email, and we'll notify you when the price and Fair Value of PT Wahana Inti Makmur Tbk materially change. Free bonus: the monthly Top-25 report of the most undervalued quality stocks.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.